Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-26T20:24:05.018Z Has data issue: false hasContentIssue false
  • English
  • Français

Homozygous mutation at cytochrome P4502D6 in an individual with schizophrenia: Implications for antipsychotic drugs, side effects and compliance

Published online by Cambridge University Press:  13 June 2014

Michael Gill ,
Ziarih Hawi  and
Marcus Webb
Marcus Webb
Affiliation:
Departments of Psychiatry and Genetics, Trinity Centre for Health Sciences, St James's Hospital, James's Street, Dublin 8, Ireland
Get access Rights & Permissions [Opens in a new window]

Abstract

We report the case of a patient with schizophrenia who has suffered severe side effects with many different antipsychotics. She is poorly compliant with treatment probably because of her experiences with medication. We determined her genotype at the CYP2D6 gene that codes for an enzyme principally involved in the metabolism of many antipsychotics. She was homozygous for the ‘B’ mutation, the most frequent of several known mutations. She therefore has no functioning CYP2D6 enzyme in common with 5%-10% of the population. This may explain why she is sensitive to quite moderate doses of antipsychotic medication, and more rational prescribing may lead to fewer side effects and increased compliance.

Keywords

Antipsychotic drugsGeneticsCYP2D6Cytochrome P450Side effects
Type
Case Reports
Information
Irish Journal of Psychological Medicine , Volume 14 , Issue 1 , March 1997 , pp. 38 - 39
Copyright
Copyright © Cambridge University Press 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Cholerton, S, Daly, A, Idle, R. The role of individual human cytochrome P450 in drug metabolism and clinical response. TiPS 1992; 13: 434–9.Google ScholarPubMed
2.Gonzalez, F. Human cytochromes P450 problems and prospects. TiPS 1992; 13: 346–52.Google ScholarPubMed
3.Meyer, J, Woggon, B, Baumann, P, Meyer, U. Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type. Eur J Clin Pharmacol 1990; 39: 613–4.CrossRefGoogle Scholar
4.Daly, AK, Armstrong, M, Monkman, SC, et al.Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. Pharmacogenetics 1991; 1: 33–41.CrossRefGoogle ScholarPubMed
5.Dahl-Puustinen, M-L, Liden, A, Aim, C, Nordin, C, Bertilsson, L. Disposition of perphenazine is related to polymorphic debrisoquine hydroxylation in human beings. Clin Pharmacol Ther 1989; 46: 78–81.CrossRefGoogle ScholarPubMed